Wellbutrin is not a tricyclic antidepressant (TCA). Its FDA labeling states explicitly that bupropion hydrochloride, the active ingredient in Wellbutrin, “is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents.” Wellbutrin belongs to a completely different drug class called norepinephrine-dopamine reuptake inhibitors (NDRIs), and it works through a distinct mechanism with a notably different side effect profile.
What Makes a Drug a TCA
Tricyclic antidepressants get their name from their chemical structure: three connected rings of atoms. The middle ring is typically seven atoms wide, and the molecule includes a specific nitrogen-containing side chain. This shared architecture is why all TCAs tend to produce a similar cluster of side effects, including dry mouth, drowsiness, constipation, difficulty urinating, weight gain, and dizziness. They were originally developed as relatives of early antipsychotic drugs and have been used for major depression since the 1950s.
Common TCAs include amitriptyline, nortriptyline, imipramine, and desipramine. These drugs work broadly across multiple brain chemical systems, which is partly why they’re effective but also why they carry significant risks. TCAs can cause dangerous heart rhythm changes and are potentially lethal in overdose. A 10-day supply at typical doses can be fatal if taken all at once.
How Wellbutrin Works Differently
Wellbutrin is classified as an aminoketone, a chemical structure with no resemblance to the three-ring TCA backbone. Rather than casting a wide net across brain chemistry the way TCAs do, Wellbutrin targets two specific chemical messengers: norepinephrine and dopamine. It blocks the recycling of both, keeping more of them active in the brain. Notably, it does not directly affect serotonin, which sets it apart from both TCAs and the more commonly prescribed SSRIs.
The way Wellbutrin boosts dopamine also varies by brain region. In the prefrontal cortex (involved in focus and decision-making), it works by blocking norepinephrine recycling, which indirectly raises dopamine levels. In the striatum (involved in motivation and reward), it blocks dopamine recycling directly. Once in your body, Wellbutrin is broken down into several active byproducts, some of which are actually more potent than the original drug.
Side Effects Compared to TCAs
The practical difference most people notice is in how these drugs feel day to day. TCAs are known for sedation, weight gain, and a group of effects caused by blocking a chemical messenger called acetylcholine: dry mouth, blurred vision, constipation, and trouble urinating. They can also worsen glaucoma and heart conditions.
Wellbutrin’s side effect profile looks quite different. The most common issues are headaches, insomnia, nausea, and elevated blood pressure. It is one of the few antidepressants that does not typically cause weight gain or sexual dysfunction. In fact, bupropion is sometimes added to other antidepressants specifically to counteract sexual side effects those drugs cause.
Both Wellbutrin and TCAs can lower the seizure threshold, but the risk with Wellbutrin is dose-dependent and rises sharply in people with specific risk factors: a personal or family history of seizures, eating disorders like bulimia or anorexia, heavy alcohol use, sleep deprivation, or a history of head injury. Stopping alcohol or benzodiazepines while on Wellbutrin also increases the risk. One emergency department study found that bupropion at normal prescribed doses was the third most common cause of drug-related new-onset seizures, behind cocaine intoxication and benzodiazepine withdrawal.
Where Each Fits in Depression Treatment
American Psychiatric Association guidelines list bupropion alongside SSRIs, SNRIs, and mirtazapine as optimal first choices for most people with major depression. TCAs, while equally effective, are generally reserved for cases where these newer options haven’t worked. The main reason is safety: TCAs carry greater overdose risk and more burdensome side effects for most patients.
Overall effectiveness across antidepressant classes is comparable. The choice between them comes down to side effect tolerance, other medical conditions, and individual response. Someone who has struggled with weight gain or sexual side effects on an SSRI might do well on Wellbutrin. Someone with chronic pain (which TCAs can help with) might benefit from a tricyclic. But the two drugs are not interchangeable substitutes, and switching between classes should be managed carefully because their mechanisms are fundamentally different.
Why the Confusion Exists
The mix-up likely comes from the fact that Wellbutrin is an antidepressant, and many people associate older antidepressants with the TCA class. Before SSRIs arrived in the late 1980s, TCAs were the dominant antidepressant category, so the terms sometimes get conflated. Wellbutrin was also first approved in the 1980s, which places it in the same era. But its chemistry, its brain targets, and its real-world effects on patients are distinct from tricyclics in every meaningful way.